Tenecteplase: Innovative Fibrinolysis for ST-Segment Elevation Myocardial Infarction (STEMI)

P and T

Volumn 28, Issue 1, 2003, Pages 20-30

  Vanscoy, Gordon J ^a   Rihn, Thomas L ^b   Koerner, Pamela H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THROMBIN INHIBITOR;

BLOOD CLOT LYSIS; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; REVIEW; SIDE EFFECT; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION;

EID: 0345133364     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Reimer KA, Lowe JE, Rasmussen MM, et al. The wavefront phenomenon of ischemic cell death: Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 1977;56:786-794.
2. Ohman EM, Harrington RA, Cannon CP, et al. Intravenous thrombolysis in acute myocardial infarction. Chest 2001;119:253S-277S.
3. Boersma E, Maas ACP, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-775.
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
5. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
6. Ross AM. New plasminogen activators: A clinical review. Clin Cardiol 1999;22:165-171.
7. TNKase™ (tenecteplase) package insert. South San Francisco, CA: Genentech, Inc; June 2000.
8. Second International Study of Infarct Survival Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
9. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
10. Activase® (alteplase) package insert. South San Francisco, CA: Genentech, Inc; June 1999.
11. International Joint Efficacy Comparison of Thrombolytics (INJECT) Investigators. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995;346:329-336.
12. GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
13. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994;91:3670-3674.
14. Stewart RJ, Fredenburgh JC, Leslie BA, et al. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem 2000;275:10112-10120.
15. Paoni NF, Keyt BA, Refino CJ, et al. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemost 1993;70:307-312.
16. Sprengers ED, Akkerman JW, Jansen BG. Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 1986;55:325-329.
17. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999;99:3050-3055.
18. DeMarco E, Rebuzzi AG, Quarant W, et al. Lack of procoagulant effect after TNK-plasminogen activator in patients with acute myocardial infarction (Abstract). Eur Heart J 1998;19(Suppl 8):5.
19. Modi NB, Fox NL, Clow FW, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a phase II study in patients with acute myocardial infarction. J Clin Pharmcol 2000;40:508-515.
20. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351-356.
21. Gibson CM, Cannon CP, Murphy SA, et al. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the Thrombolysis in Myocardial Infarction 10B trial. Am J Cardiol 1999;84:976-980.
22. Gibson M, Ryan KA, Kelly MB, et al. Slower global flow in all three epicardial arteries after thrombolysis is related to adverse outcomes (Abstract). Circulation 1998;98(Suppl I):I-698.
23. Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration on TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial. Am Heart J 1999;137:786-791.
24. Wang-Clow F, Fox NL, Cannon CP. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am Heart J 2001;141:33-40.
25. th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 18-21, 2001.
26. rd Scientific Sessions of the American Heart Association (Abstract), New Orleans, LA, November 10-15, 2000.
27. ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-722.
28. nd Scientific Sessions of the American Heart Association, Atlanta, GA, November 7, 1999.
29. nd Annual Congress of the European Society of Cardiology, Amsterdam, The Netherlands, August 29, 2000.
30. Collen D. Towards improved thrombolytic therapy. Lancet 1993;342:34-36.
31. Cohen M, Demers C, Gurfinkel E, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337: 447-452.
32. Antman EM and the TIMI 11B Investigators. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: A double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Am Heart J 1998;135:S353-S360.
33. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART 2). Circulation 2001;104(6):648-652.
34. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
35. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001;357:1905-1914.
36. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. For the WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA project: registration procedures, event rates, and case fatality in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
37. Chambless L, Keil U, Dobson A, et al. Population versus clinical view of case fatality for acute coronary heart disease: Results from the WHO MONICA Project 1985-1990. The Multinational Monitoring of Trends and Determinants in Cardiovascular Disease. Circulation 1997;96:3849-3859.